In the UK, semaglutide 2.4 mg is recommended by NICE (TA875) for use within specialist weight management services with scheduled monitoring
GLP-1 Market Share, By Indication, 2025 (%) The obesity and weight management segment held a 28% share of the market in 2025 and is expected to grow at the fastest CAGR of 18.6% during the projection period
A qualified provider evaluates your health history, weight goals, and risk factors to decide whether GLP-1 therapy is appropriate for you
A Cardiovascular Mode of Action Trial of semaglutide is currently being conducted (NCT04032197)
41 If the post-dose fasting time continues to extend, will the pharmacokinetics of semaglutide be more affected
These creams and peels can be used on various areas of the body, not just on the face, but also the arms, legs, chest and torso